Navigation Links
USC researchers discover novel way to develop tumor vaccines
Date:3/2/2008

LOS ANGELES, March 2, 2008 Researchers at the University of Southern California (USC) have uncovered a new way to develop more effective tumor vaccines by turning off the suppression function of regulatory T cells. The results of the study, titled A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression, will be published in Nature Medicine on March 2, 2008.

Under normal circumstances, regulatory T cells inhibit the immune system to attack its own cells and tissues to prevent autoimmune diseases. Cancer cells take advantage of regulatory T cells' suppressor ability, recruiting them to keep the immune system at bay or disabling the immune systems attack provoked by tumor vaccines. says Si-Yi Chen, M.D., Ph.D., professor of immunology and molecular microbiology at the USC/Norris Comprehensive Cancer Center and the Keck School of Medicine of USC. Our study provides a new vaccination strategy to overcome the regulatory T cells immune suppression while avoiding non-specific overactivation of autoreactive T cells and pathological autoimmune toxicities.

The study identified a new molecular player called A20, an enzyme that restricts inflammatory signal transduction in dendritic cells. When it is inhibited, the dendritic cells overproduce an array of cytokines and co-stimulatory molecules that triggers unusually strong immune responses that cannot be suppressed by regulatory T cells. The resulting hyperactivated immune responses triggered by A20-deficient dendritic cells are capable of destroying various types of tumors that are resistant to current tumor vaccines in mice.

Through a series of immunological studies, we have identified A20 as an essential antigen presentation attenuator that prevents the overactivation and excessive inflammation of the dendritic cells, which, in turn, restricts the potency of tumor vaccines, says Chen.

The immune systems dendritic cells are the guardian cells of the immune systems and play an important role in activating immune responses to recognize and destroy tumor cells. Tumor vaccines have been designed and developed to incite the immune response to cancer cells so that the immune system can attack and destroy cancer cells. However, discovering A20s role in restricting immune responses has led to a method for blocking tumors from using regulatory T cells for protection.

Despite intensive efforts, tumor vaccines have been largely ineffective in causing tumor regression in the clinic, says Chen. The vaccination approach we developed inhibits the key inhibitor in tumor antigen-loaded dendritic cells to selectively hyperactivate immune responses and to tip the balance from immune suppression in tumor-bearing hosts or cancer patients to effective antitumor immunity.

This approach is capable of overcoming the regulatory T cells suppression mechanism and will allow for a new generation of tumor vaccines to be developed. The next step is to translate these findings into a human clinical trial, says Chen.


'/>"/>

Contact: Jennifer Chan
chanj@usc.edu
323-442-2830
University of Southern California
Source:Eurekalert

Related medicine news :

1. St. Jude Researchers Find Key Step in Programmed Cell Death
2. St. Jude researchers find key step in programmed cell death
3. Mayo Researchers Look for Explanation Behind High Incidence of Diabetes Among Asian Indians
4. Mayo researchers look for explanation behind high incidence of diabetes among Asian Indians
5. UT Southwestern researchers investigate predictors for sickle-cell-anemia complications
6. Researchers find possible target to treat deadly bloodstream infections
7. Rutgers researchers unlock mysteries of vitamin A metabolism during embryonic development
8. U of Minn researchers discover genetic cancer link between humans and dogs
9. New genetic association with schizophrenia found by researchers
10. Thomson Scientific To Honor Australias Top Researchers With Dedicated Australian Research Day
11. This is your brain on jazz: researchers use MRI to study spontaneity, creativity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... certification process to promote standards of excellence for the field of eating disorders, ... March 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017 ... single-use, self-contained, illuminating medical devices, today announced regulatory ... Health Surveillance Agency (or Agência Nacional de Vigilância ... first single-use, cordless surgical retractor with integrated LED ... optimal access, illumination and exposure of a tissue ...
(Date:10/2/2017)... COPENHAGEN, Denmark , Oct. 2, 2017 The ... tool in the struggle to reverse the tide of prescription ... plan for regulating their medicine intake and stepping down their ... is set to launch in December 2017; the first 100,000 ... access. Learn more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
Breaking Medicine Technology: